Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3–4 NSCLC patients

Table 3 Comparison of the performance of PPS with other previous signatures

	NSCLC	Adenocarcinoma				Squamous				Pubmed ID	Study subjects
	1 year	3 year	5 year	1 year	3 year	5 year	1 year	3 year	5 year	Pubmed ID	Study subjects
PPS	0.784	0.808	0.764	0.802	0.806	0.727	0.757	0.812	0.788	NULL	Stage 3 & 4 NSCLC
Jia Li, et al	0.596	0.539	0.415		NULL			NULL		32,020,214	NSCLC
Jie Yao, et al	0.629	0.633	0.564		NULL			NULL		33,403,045	NSCLC
Han Wang, et al		NULL		0.614	0.489	0.445		NULL		32,989,393	LUAD
Jie Zhu, et al				0.587	0.594	0.691		NULL		32,695,805	LUAD
Deng gang Fu, et al		NULL			NULL		0.596	0.694	0.631	33,005,178	LUSC
Jili Hou, et al	NULL				NULL		0.593	0.537	0.593	33,466,167	LUSC

ISSN: 1755-8794